Navigation Links
San Diego-Based Wellaho Receives FDA Approval For its Mobile and Web Platform for Patients with Chronic Conditions
Date:2/19/2013

SAN DIEGO, Feb. 19, 2013 /PRNewswire/ -- Sanitas, Inc., a San Diego company developing mobile and web solutions for outpatients with chronic conditions, announced today that it has received approval from the US Food and Drug Administration, (FDA) as a 510(K) class II medical device for Wellaho, its proprietary mobile and web platform.

Wellaho's Personalized Outpatient Management SystemTM - currently deployed in a number of clinical studies at UC San Diego Health Services - is a physician-directed, web-based and mobile platform that allows providers to supervise and monitor patients between office visits in a secure, HIPAA compliant environment, while enabling patients to access their medical information, monitor their condition, stream relevant educational materials and connect securely to their doctors and healthcare team.

Naser Partovi , CEO of Sanitas, Inc., said of the Wellaho system, "Patients with chronic conditions need a web of care, coming from the best that providers and technology can offer. Given the tsunami of new apps and technologies that hit the market each year, both patients and providers need the highest validation for the products and services they use. Now, with the FDA's approval, Wellaho offers one more reason for providers and patients to trust that we can provide a safe, secure, and effective solution for managing their care."

About Sanitas, Inc.

Sanitas Inc. is a privately held San Diego company founded in 2010. Wellaho is the company's proprietary web and mobile platform serving patients with chronic conditions including: diabetes, congestive heart failure, kidney disease, COPD, asthma, hypertension, breast cancer, sleep disordered breathing, and obesity. Patients can view their health records (CCDs) and easily monitor their medications, weight, exercise and activity levels, blood glucose levels, blood pressure and other symptoms. Meanwhile, the patients' doctors and medical team can use Wellaho to monitor their patients' conditions between office visits.  Social networking and self-education are integral aspects of Wellaho's platform, allowing patients and their families to learn more about their disease while staying connected to their medical team in a secure, HIPPA compliant online environment.  Sanitas is actively engaged with UC San Diego Health Services in several clinical studies including diabetes, congestive heart failure and weight management.

For more information, please contact moya@wellaho.com


'/>"/>
SOURCE Sanitas, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
2. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
3. Nephros Receives 510(k) Clearance for Hemodiafiltration System
4. ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System
5. BONESUPPORT Receives Red Herring 2012 Top 100 Europe Award
6. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
7. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
8. Alexza Receives Complete Response Letter for Adasuve™ NDA
9. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
10. Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering
11. New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... NEW YORK , Dec. 5, 2016 Special ... collection of samples such as fluid and cells from organs ... advanced features, shapes, and sizes. The global market for special ... increasing geriatric population. In terms of revenue, the global special ... of 7.4% during the forecast period (2016–2026) and is expected ...
(Date:12/5/2016)... THE WOODLANDS, Texas , Dec. 5, 2016 /PRNewswire/ ... ) announced top-line results today from a Phase 2 ... inhibitor, conducted by Lexicon in collaboration with JDRF, the ... The purpose of this Phase 2 clinical trial, ... assess the effects of a once-daily 400 mg dose ...
(Date:12/5/2016)... 5, 2016 According to a new market ... Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), Application (Hyaline Cartilage, ... market is projected to reach USD 779.8 Million by 2021 from ... during the forecast period of 2016 to 2021. ... ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... ... measurement firms. The ranking is based on reported data for 2015 performance ... health systems, ambulatory surgical centers, clinically integrated networks, and many of the nation’s ...
(Date:12/6/2016)... ... December 06, 2016 , ... The NALA, a boutique marketing ... Bear Cancer Foundation (TBCF), a nonprofit 501(C)(3) organization providing financial and emotional support ... Obispo counties. To assist TBCF, the NALA recently hosted a Thanksgiving food drive that ...
(Date:12/6/2016)... ... December 06, 2016 , ... Healthcare leaders from ... regulations at the 7th annual Health IT Leadership Summit, to be held Wed., ... for the Centers for Medicare & Medicaid Services (CMS), will be the morning ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... is proud to announce it has added CXC Solutions (CXC) as a new ... These solutions are tailored to help benefits advisors reduce operating costs and ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation involving ... and development, largely due to its potential for revolutionizing human disease treatment. There ... human induced pluripotent stem cells (hiPSCs). , Both platforms have distinct advantages ...
Breaking Medicine News(10 mins):